Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) have been given an average recommendation of “Moderate Buy” by the seventeen ratings firms that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $204.14.

Several research firms recently issued reports on JAZZ. Piper Sandler cut their target price on Jazz Pharmaceuticals from $197.00 to $193.00 in a research report on Thursday, May 5th. Royal Bank of Canada cut their target price on Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating for the company in a research report on Wednesday, March 2nd. StockNews.com cut Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 10th. Cowen increased their target price on Jazz Pharmaceuticals from $200.00 to $225.00 in a research report on Thursday, May 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 2nd.

In other Jazz Pharmaceuticals news, SVP Samantha Pearce sold 8,487 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $155.00, for a total transaction of $1,315,485.00. Following the completion of the sale, the senior vice president now directly owns 11,309 shares of the company’s stock, valued at approximately $1,752,895. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Anne Oriordan sold 466 shares of Jazz Pharmaceuticals stock in a transaction on Monday, May 9th. The shares were sold at an average price of $148.95, for a total value of $69,410.70. Following the sale, the director now directly owns 9,245 shares of the company’s stock, valued at $1,377,042.75. The disclosure for this sale can be found here. Insiders have sold a total of 39,567 shares of company stock valued at $6,096,461 over the last three months. 4.40% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Teachers Retirement System of The State of Kentucky increased its holdings in shares of Jazz Pharmaceuticals by 8.8% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 69,912 shares of the specialty pharmaceutical company’s stock valued at $10,883,000 after acquiring an additional 5,679 shares during the period. Bank of America Corp DE grew its stake in Jazz Pharmaceuticals by 18.7% during the 1st quarter. Bank of America Corp DE now owns 301,951 shares of the specialty pharmaceutical company’s stock worth $47,004,000 after buying an additional 47,553 shares during the last quarter. Neuberger Berman Group LLC grew its stake in Jazz Pharmaceuticals by 51.2% during the 1st quarter. Neuberger Berman Group LLC now owns 5,186 shares of the specialty pharmaceutical company’s stock worth $807,000 after buying an additional 1,755 shares during the last quarter. Greylin Investment Mangement Inc. grew its stake in Jazz Pharmaceuticals by 24.2% during the 1st quarter. Greylin Investment Mangement Inc. now owns 4,340 shares of the specialty pharmaceutical company’s stock worth $676,000 after buying an additional 846 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Jazz Pharmaceuticals by 89.2% during the 1st quarter. The Manufacturers Life Insurance Company now owns 129,235 shares of the specialty pharmaceutical company’s stock worth $20,184,000 after buying an additional 60,938 shares during the last quarter. Institutional investors and hedge funds own 93.23% of the company’s stock.

NASDAQ JAZZ opened at $149.05 on Thursday. The stock’s 50-day moving average price is $152.53 and its 200-day moving average price is $146.02. The company has a quick ratio of 2.06, a current ratio of 3.39 and a debt-to-equity ratio of 1.66. Jazz Pharmaceuticals has a 52 week low of $117.64 and a 52 week high of $186.22. The company has a market capitalization of $9.31 billion, a P/E ratio of -19.85, a price-to-earnings-growth ratio of 1.19 and a beta of 0.80.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The specialty pharmaceutical company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.00 by $0.13. Jazz Pharmaceuticals had a positive return on equity of 22.45% and a negative net margin of 13.63%. The firm had revenue of $813.72 million for the quarter, compared to the consensus estimate of $853.73 million. During the same quarter last year, the company earned $3.42 earnings per share. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. Research analysts anticipate that Jazz Pharmaceuticals will post 14.73 EPS for the current year.

About Jazz Pharmaceuticals (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Featured Articles

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Want More Great Investing Ideas?

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.